pharmaphorum

APRIL 26, 2024

Gain insights into market access strategies for 2024 with a deep dive featuring perspectives from industry leaders such as Alexion, Putnam, Inizio Advisory, and insights from Reuters Pharma US.

52

52

European Pharmaceutical Review

MARCH 20, 2024

According to a report by Arizton, the Europe laboratory information management system (LIMS) market is expected to reach $912.47 The market is growing at a CAGR of 10.16 Increased concerns over data integrity , validity, and security are also contributing factors to the expansion of the European LIMS market, the report stated.

96

96

Drug Topics

NOVEMBER 7, 2023

A Q&A with Ginny Langbehn, vice president of marketing and communications at American Associated Pharmacies, about different strategies pharmacies can use to bring in new customers.

Communication 211

Communication 211

pharmaphorum

JANUARY 10, 2024

Discover the top 5 pharma marketing trends to watch out for in 2024. From personalised marketing strategies to the power of video and omnichannel communication, explore how patient-centric approaches and generative AI are shaping the future of pharmaceutical marketing.

Communication 117

Communication 117

Fierce Pharma

APRIL 4, 2024

Amylyx Pharmaceuticals is keeping a promise by pulling the amyotrophic lateral sclerosis (ALS) therapy Relyvrio off the market after the drug failed in a confirmatory trial. Amylyx is keeping a promise by pulling the amyotrophic lateral sclerosis (ALS) therapy Relyvrio off the market after the drug failed in a confirmatory trial.

121

121

Drug Topics

MAY 31, 2023

The frequency of drug manufacturer coupon utilization is associated with more market competition—but not patients’ out-of-pocket costs.

187

187

European Pharmaceutical Review

MARCH 27, 2024

A report by Allied Market Research has predicted that the global pyrogen testing market will value $3.3 The market is predicted to grow at a CAGR of 8.2 A higher incidence of infectious diseases is a major contributing factor for the expansion of the pyrogen testing market. billion by 2032.

FDA 75

FDA 75

European Pharmaceutical Review

MARCH 19, 2024

the global continuous bioprocessing market is expected to value $1,067.8 While the market was valued at $255.9 Overall, the market is expanding due to a greater demand for biologics , technological advancements, plus regulatory support for continuous manufacturing approaches, the report noted. million by 2031.

Documentation 74

Documentation 74

STAT

APRIL 15, 2024

surged to 36% from just 5% during the first week of April, thanks to the expanding reach that CVS Health has over the prescription drug market. However, Hyrimoz is jointly marketed with Cordavis, a new subsidiary that CVS created last August specifically to sell any number of biosimilar medicines in the U.S.

Insurance 130

Insurance 130

European Pharmaceutical Review

MARCH 28, 2024

The global pharmaceutical and biotechnology environmental monitoring market valued $24 billion in 2023, according to a report by Verified Market Research. As pharmaceutical and biotechnology companies grow, there is concurrent demand for regular environmental monitoring across new markets, the research explained.

86

86

Drug Topics

APRIL 13, 2023

As more adalimumab biosimilars are poised to enter the market, manufacturers, payers, and patient advocates are preparing to navigate potentially turbulent waters.

185

185

European Pharmaceutical Review

FEBRUARY 22, 2024

A report by Towards Healthcare has forecasted that the advanced drug delivery market will value $375.86 billion, the market witnessed “remarkable advancements that promise to reshape healthcare landscapes across the globe”. In 2023, these systems captured 48 percent share of the market, according to report’s author.

FDA 89

FDA 89

STAT

APRIL 4, 2024

Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and Canada, ending a multi-year saga for patients with the rare neurodegenerative disease. Relyvrio was approved by the Food and Drug Administration in 2022 , based on data that showed a modest slowing of disease progression.

142

142

pharmaphorum

FEBRUARY 22, 2024

In a dynamic healthcare market, securing top talent is essential for the success of any organisation. Advanced Clinical looks at innovative recruitment strategies and solutions to help you attract and retain the best healthcare professionals.

113

113

pharmaphorum

JANUARY 31, 2024

Discover the secret to successful patient influencer marketing and how it can benefit your healthcare organisation. Reverba offers innovative patient engagement solutions and strategies that utilise the power of authentic patient influencers.

117

117

STAT

APRIL 4, 2024

market, Humira (adalimumab) last year began facing competition from multiple less-expensive biosimilar versions of the blockbuster therapy. Some employees may find positions elsewhere in the company, but they are mostly being pulled from the field. After two decades on the U.S.

138

138

European Pharmaceutical Review

MARCH 15, 2024

According to research published by Coherent Market Insights, the global mycoplasma testing market is anticipated to reach $1,907.6 The market is set to witness a compound annual growth rate (CAGR) of 9.7 What is driving and limiting growth in the market? However, financial limitations are impacting the market too.

Compounding 90

Compounding 90

European Pharmaceutical Review

DECEMBER 4, 2023

A report published by MarketsandMarkets has estimated that the pharmaceutical excipients market will value $14.9 This is compared to the expected revenue for the market in 2023 reaching $10.7 According to the research, a key limitation for the market are the high development costs associated with novel excipients.

Pharmaceutical Companies 94

Pharmaceutical Companies Pharmaceutical Companies 94

European Pharmaceutical Review

FEBRUARY 20, 2024

A report from Data Bridge Market Research has predicted that the upstream bioprocessing market will value $14,256.78 Additionally, the research calculated that market is anticipated to undergo a CAGR of 6.85 million by 2029. percent between 2022 and 2029.

Process Improvement 85

Process Improvement 85

Fierce Healthcare

FEBRUARY 23, 2024

Walgreens is closing its remaining VillageMD primary care clinics in Florida. | The announcement does not come as a total surprise, as Walgreens first disclosed its plans to close 60 underperforming VillageMD clinics and exit five markets last fall.

118

118

Pharmacy Times

DECEMBER 19, 2023

Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, discusses the dynamic landscape of the biosimilars market, providing key insights into its current status and future projections.

132

132

Fierce Healthcare

OCTOBER 18, 2023

Conquering 5 Common Healthcare Marketing Challenges | Healthcare marketing is tough. Learn about 5 common healthcare marketing challenges and how health education content helps you face them head-on.

98

98

pharmaphorum

OCTOBER 17, 2023

In this latest instalment of the pharmaphorum podcast, web editor Nicole Raleigh speaks with life sciences advisor Randall Hein, CEO of Heinsight LLC, and health sciences marketing expert Krystle Buntemeyer, CEO of SCORR Marketing, about the trends and changes for health sciences marketing over the past few years.

115

115

Pharma Marketing Network

JULY 26, 2023

The Food and Drug Administration (FDA) plays a critical role in regulating the pharmaceutical industry and ensuring that medications and medical devices marketed to the public are safe, effective, and appropriately labeled.

FDA 97

FDA Pharmaceutical Companies Pharmaceutical Companies Labelling 97

European Pharmaceutical Review

FEBRUARY 14, 2024

A report by Allied Market Research predicts that the global pharmaceutical suspension market will reach $83.8 billion in 2022, the research expected that the market will reach a CAGR of 4.2 In contrast, in 2022, the oncology sector within the market accounted for over a quarter of the global market.

77

77

Fierce Healthcare

OCTOBER 18, 2023

Seniors are forced to navigate a convoluted Medicare Advantage (MA) landscape for healthcare coverage, often only to be denied care, experts told legislators during a Senate Finance Committee heari | Senators and experts agreed Wednesday that marketing practices from Medicare Advantage plans are often overwhelming for seniors.

138

138

Fierce Healthcare

SEPTEMBER 18, 2023

Seniors are becoming increasingly overburdened by marketing efforts from private Medicare plans, and low-income beneficiaries are twice as likely to file complaints regarding fraudulent phone calls | Fraudulent marketing practices are affecting low-income seniors looking for Medicare plans more than higher-income seniors, a new study has found.

124

124

Drug Topics

MAY 15, 2023

Marketing costs money, so be sure to spend wisely.

Independent Pharmacies 187

Independent Pharmacies 187

Fierce Healthcare

JANUARY 23, 2024

The Senate Finance Committee sent letters to multiple insurance marketplaces, seeking additional details on the marketing strategies they use to reach potential Medicare Advantage enrollees. |

Insurance 114

Insurance 114

Fuld

FEBRUARY 3, 2024

Our services include: Go-to-market strategy Market size Growth potential and opportunities Key trends and drivers Competitive landscapes Market share analysis M&A and iactivity Competitive intelligence The post Strategic Market Research appeared first on Fuld & Co.

52

52

PharmExec

OCTOBER 13, 2023

Exploring the pharma and biotech financing, M&A, and stock market pictures through the first half of 2023—and implications for the future, as market challenges continue to weigh heavily in senior management decision-making.

104

104

pharmaphorum

APRIL 4, 2024

Amylyx confirmed today that it will withdraw its amyotrophic lateral sclerosis (ALS) therapy Relyvrio/Albrioza from the market in the US and Canada, shortly after the drug failed a clinical trial.

98

98

Fierce Pharma

MARCH 22, 2024

and China, Eli Lilly’s CEO said the Indianapolis-based company remains committed to the Chinese market. At a time of heightened geopolitical tensions between the U.S. David Ricks’ visit to China comes as Lilly has several key drug applications under review at local regulators.

113

113

Fierce Pharma

MARCH 8, 2024

After reporting the failu | After reporting the failure of a confirmatory trial of its amyotrophic lateral sclerosis drug Relyvrio (AMX0035), Amylyx Pharmaceuticals is uncertain whether it will pull the treatment from the market in the U.S. and in Canada, where it is known as Albrioza.

115

115

Mission-Driven Marketing Blog

APRIL 22, 2024

Welcome to Tapp Green’s guide to leveraging the top four storytelling models to capture market share and gain a competitive edge in the Green Tech Sector.

52

52

pharmaphorum

SEPTEMBER 7, 2023

In today’s episode, sponsored by Veeva, we’ll hear a roundtable discussion on this fascinating topic featuring Victoria Serra Gittermann, European customer experience lead at Veeva Systems and Sebastian Noel, Veeva’s director of multichannel strategy – moderating a discussion with two executives with first-hand experience leading this change: Andy (..)

121

121

STAT

MARCH 18, 2024

So when new market developments threaten to diminish or wipe away that revenue stream, PBMs find crafty ways to keep as much of those dollars as possible — often at the expense of employers. PBMs, the middlemen of drug pricing negotiations, also claim portions of those lucrative rebates for themselves.

Documentation 145

Documentation Pharmaceutical Companies Pharmaceutical Companies Insurance 145